Arimune is a drug that exposes cancer cells inside a tumour to anti-cancer agents, and was created by a clinical stage nanomedicine company called CytImmune, founded in 1988.
First of all... What is a tumour?
A tumour is a general term for a mass. It can refer to benign (slow growing, generally harmless) or malignant (fast growing, cancerous) growths. Tumours do not necessarily mean cancer. Cancer is a threatening type of tumour, but not all tumours are cancer.
It is made from...
- TNF-Target Molecules
- Therapeutic Payload
- Colloidal Gold Nanoparticle
PEG stands for PolyEthlene Glycol:
It is a water-absorbing molecule that covers the gold nanoparticles like tiny hairs, and the key to the stealthy nature of the Arimune platform.
This means that it attracts and holds a protective shield around the nanotherapy as it passes through the body, acting as a water shield for the the nanomedicne.
TNF stands for Tumour Necrosis Factor:
TNF breaks down the blood vessel architecture inside the tumours. This means it makes the cancer cells inside the tumour vulnerable to anti-cancer agents, or drugs.
Something special about the Gold Nanoparticle:
- It is precisely sized, to stop the permanent leakiness of tumour blood vessels
- It has low toxicity and regulators understand its safety profile, as it has been used therapeutically for decades